Clinical Trials

86 enrolled

Locally Recurrent Skin Squamous Cell Carcinoma

NCT07252739 2026-03-16

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

130 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Neoplasms

NCT06239220 2026-02-27

PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

25 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06855212 2026-02-20

Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC

21 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT07063212 2026-02-19

A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)

40 enrolled

Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06369259 2026-02-11

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

33 enrolled

Advanced Colorectal Cancer

NCT06915142 2026-01-26

A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour

300 enrolled

Advanced Malignant Tumour

NCT06194656 2026-01-16

Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma

81 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06540326 2025-12-22

Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab

100 enrolled

Colorectal Cancer Metastatic

NCT05959356 2025-12-17

CEIL

198 enrolled

Colorectal Neoplasms

NCT07253896 2025-11-28

Efficacy and Safety of AK104 Combined With Chemotherapy and Cetuximab or Bevacizumab

40 enrolled

Colorectal Neoplasms

NCT05576896 2025-10-20

Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory

43 enrolled

Colorectal Neoplasms

NCT07183865 2025-09-19

Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)

44 enrolled

Locally Recurrent Rectal Cancer

NCT05706779 2025-09-02

NEORAF

30 enrolled

Colorectal Neoplasms

NCT06856213 2025-08-21

ERBIOTAX

65 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06935188 2025-07-18

Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC

98 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06978400 2025-05-18

A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer

64 enrolled

Neoplasms, Colorectal Neoplasms

NCT06908031 2025-05-14

CRIT

49 enrolled

Rectal Neoplasms

NCT06477692 2025-04-08

Invert-Prospective Phase II Randomized Trial of Involved Nodal Versus Elective Neck RadioTherapy

80 enrolled

Head and Neck Neoplasms

NCT02128906 2025-03-26

Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

120 enrolled

Carcinoma, Squamous Cell, Laryngeal Diseases

NCT06869473 2025-03-14

AVEC-119

67 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT06763029 2025-02-27

VICPROIRI

36 enrolled

Colorectal Neoplasms

NCT06640166 2025-02-12

ECLYPse

25 enrolled

Colonic Neoplasms, Colorectal Neoplasms

NCT06411600 2024-11-08

BRAVE

94 enrolled

Colorectal Neoplasms

NCT03874026 2024-11-07

CIFRA

34 enrolled

Colorectal Neoplasms

NCT05628038 2024-10-01

TORCH-R

93 enrolled

Rectal Neoplasms

NCT06603376 2024-09-19

Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer

75 enrolled

Colorectal Neoplasms

NCT06575127 2024-08-28

Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study

60 enrolled

Colonic Neoplasms, Neoplasms

NCT06547203 2024-08-09

Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study

34 enrolled

Colorectal Neoplasms

NCT06440902 2024-06-04

Exploration of Therapeutic Strategies for NeoRAS Wild-type Metastatic Colorectal Cancer Based on Circulating Tumor DNA

1,100 enrolled

Colorectal Cancer Metastatic

NCT06151743 2024-04-30

Neoadjuvant PD-1 Inhibitor Combined With Cetuximab and Platinum in Resectable Locally Advanced Hypopharyngeal Carcinoma

32 enrolled

Locally Advanced Hypopharyngeal Carcinoma

NCT06321081 2024-03-20

ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC

60 enrolled

Colorectal Neoplasms

NCT05260671 2023-10-18

Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN

48 enrolled

Head and Neck Neoplasms, Neoplasm Metastasis, Recurrence

NCT05962502 2023-08-31

Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy

54 enrolled

Colorectal Neoplasms

NCT05725200 2023-02-21

EVIDENT

40 enrolled